A.Yu. BaranovskIy, N.V. MARCHENKO, U.A. MITELGLIK, K.L. RAYKHELSON

I.I. Mechnikov North-Western State Medical University, Kirochnaya St., 41, St. Petersburg, Russian Federation, 191015

Baranovskiy A.Yu. — D. Med. Sc., Professor, Head of the Department of Gastroenterology and Dietology, tel. +7-921-937-70-97, e-mail: baranovsky46@mail.ru

Marchenko N.V. — Assistant of the Department of Gastroenterology and Dietology, tel. +7-921-657-01-26, e-mail: dr.marchenko@gmail.com

Mitelglik U.A. — Assistant of the Department of Gastroenterology and Dietology, tel. +7-921-913-32-22, e-mail: ule4ka-med@mail.ru

Raykhelson K.L. — Cand. Med. Sc., Associate Professor of the Department of Gastroenterology and Dietology, tel. +7-911-911-01-43, e-mail: kraikhelson@mail.ru

This review article presents the historical background and the main characteristics of tumor necrosis as well as its role in the development of autoimmune disorders. The results of international studies of this cytokine in autoimmune hepatitis and primary biliary cirrhosis are also provided.

Key words: autoimmune hepatitis, primary biliary cirrhosis, alfa tumor necrosis factor.

 

REFERENCES

1. Pfeffer K., Matsuyama T., Kundig T.M. et al. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell, 1993, vol. 7, no. 73, pp. 457-467.

2. Rothe J., Lesslauer W., Lotscher H. et al. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature, 1993, no. 364, pp. 798-802.

3. Pasparakis M., Alexopoulou L., Episkopou V., Kollias G. Immune and inflammatory responses in TNF alpha-deficient micea critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J. Exp. Med, 1996, no. 184, pp. 1397-1411.

4. Flynn J.L., Goldstein M.M., Chan J. et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity, 1995, no. 2, pp. 561-572.

5. Daugherty L.C., Seal R.L., Wright M.W., Bruford E.A. Gene family matters: expanding the HGNC resource. Hum Genomics, 2012, vol. 6, no. 1, p. 4, available at: http://www.gene.ucl.ac.uk/nomenclature/genefamily/tnftop.html

6. Gaur U., Aggarwal B.B. Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem Pharmacol, 2003, vol. 66, no. 8, pp. 1403-1408.

7. Aggarwal B.B. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol, 2003, vol. 3, no 9, pp. 745-756.

8. O’Malley W.E., Achinstein B., Shear M.J. Action of bacterial polysaccharide on tumors: II. Damage of Sarcoma 37 by serum of mice treated with Serratia marcescens polysaccharide, and induced tolerance. J Natl Cancer Inst, 1962, vol. 29, pp. 1169-1175.

9. Carswell E.A., Old L.J., Kassel R.L. et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA, 1975, vol. 72, no. 9, pp. 3666-3670.

10. Aggarwal B.B., Kohr W.J., Hass P.E. Human tumor necrosis factor. Production, purification, and characterization. J Biol Chem, 1985, vol. 260, no. 4, pp. 2345-2354.

11. Gray P.W., Aggarwal B.B., Benton C.V. Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity. Nature, 1984, vol. 312, no. 5996, pp. 721-724.

12. Aggarwal B.B., Gupta S.C., Kim J.H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood, 2012, vol. 119, no. 3, pp. 651-665.

13. Hsu H., Xiong J., Goeddel D.V. The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell, 1995, vol. 81, no. 4, pp. 495-504.

14. Bazzoni F., Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med, 1996, vol. 334, no. 26, pp. 1717-1725.

15. Morgan M.J., Liu Z.G. Reactive oxygen species in TNF-alpha-induced signaling and cell death. Mol Cells, 2010, vol. 30, no. 1, pp. 1-12.

16. Aggarwal B.B. Nuclear factor-kappaB: the enemy within. Cancer Cell, 2004, vol. 6, no. 3, pp. 203-208.

17. Aggarwal B.B. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol, 2003, vol. 3, no. 9, pp. 745-756.

18. Natoli G., Costanzo A., Moretti F. et al Tumor necrosis factor (TNF) receptor 1 signaling downstream of TNF receptor-associated factor 2. Nuclear factor kappaB (NFkappaB)-inducing kinase requirement for activation of activating protein 1 and NFkappaB but not of c-Jun N-terminal kinase/stress-activated protein kinase. J Biol Chem, 1997, vol. 272, no. 42, pp. 26079-26082.

19. Ermolaeva M.A., Michallet M.C., Papadopoulou N. et al. Function of TRADD in tumor necrosis factor receptor 1 signaling and in TRIF-dependent inflammatory responses. Nat Immunol, 2008, vol. 9, no. 9, pp. 1037-1046.

20. Sedgwick J.D., Riminton D.S., Cyster J.G., Korner H. Tumor necrosis factora master-regulator of leukocyte movement. Immunol. Today, 2000, no. 21, pp. 110-113.

21. Giroir B.P., Johnson J.H., Brown T. et al. The tissue distribution of tumor necrosis factor biosynthesis during endotoxemia. J. Clin Invest, 1992, no. 90, pp. 693-698.

22. Feldmann M., Brennan F.M., Elliott M.J. et al. TNF alpha is an effective therapeutic target for rheumatoid arthritis. Ann N Y Acad. Sci, 1995, no. 766, pp. 272-278.

23. Beutler B., Cerami A. The biology of cachectin/TNF-a primary mediator of the host response. Annu. Rev. Immunol, 1989, no. 7, pp. 625-655.

24. Kassiotis G., Kollias G. Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level implications for pathogenesis and therapy of autoimmune demyelination. J. Exp. Med, 2001, no. 193, pp. 427-434.

25. Kollias G., Douni E., Kassiotis G., Kontoyiannis D. On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Immunol. Rev, 1999, no. 169, pp. 175-194.

26. Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat. Rev. Immunol, 2002, no. 2, pp. 364-371.

27. Papadakis K.A., Targan S.R. Tumor necrosis factorbiology and therapeutic inhibitors. Gastroenterology, 2000, no. 119, pp. 1148-1157.

28. Baeten D., Kruithof E., Van den Bosch F. et al. Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximaba new perspective on the role of host defence in the pathogenesis of the disease?. Ann Rheum. Dis, 2003, no. 63, pp. 829-834.

29. Mohan A.K., Cote T.R., Siegel J.N., Braun M.M. Infectious complications of biologic treatments of rheumatoid arthritis. Curr. Opin. Rheumatol, 2003, no. 15, pp. 179-184.

30. Jirillo E., Caccavo D., Magrone T. et al. The role of the liver in the response to LPS: experimental and clinical findings. J Endotoxin Res, 2002, vol. 8, no. 5, pp. 319-327.

31. Allenov M.N. Kliniko-patogeneticheskaya kharakteristika autoimmunnykh narushenii pri virusnom gepatite: avtoref. dis. … d-ra med. Nauk [Clinico-pathogenetic characteristic of autoimmune disorders in viral hepatitis. Synopsis of the dis. Dr. med. Sci.]. Saint Petersburg, 2006. 39 p.

32. Dumoulin F.L., Leifeld L., Honecker U. et al. Intrahepatic Expression of Interleukin-1b and Tumor Necrosis Factor-a in Chronic Hepatitis C. J Infect Dis, 1999, vol. 180, no. 5, pp. 1704-1708.

33. Löhr H.F., Schlaak J.F., Gerken G. et al. Phenotypical analysis and cytokine release of liver-infiltrating and peripheral blood Tlymphocytes from patients with chronic hepatitis of different etiology. Liver, 1994, vol. 14, no. 3, pp. 161-166.

34. Neuman M.G., Schmilovitz-Weiss H., Hilzenrat N. et al. Markers of inflammation and fibrosis in alcoholic hepatitis and viral hepatitis C. Int J Hepatol, 2012, doi: 10.1155/2012/231210.

35. Jampana S.C., Khan R. Pathogenesis of alcoholic hepatitis: Role of inflammatory signaling and oxidative stress. World J Hepatol, 2011, vol. 3, no. 5, pp. 114-117.

36. Tilg H. Cytokines and liver diseases. Can J Gastroenterol, 2001, vol. 15, no. 10, pp. 661-668.

37. Osawa Y., Hoshi M., Yasuda I. et al. Tumor necrosis factor-α promotes cholestasis-induced liver fibrosis in the mouse through tissue inhibitor of metalloproteinase-1 production in hepatic stellate cells. PLoS One, 2013, doi: 10.1371/journal.pone.0065251.

38. Jin P., Shao Y. Expression and significance of interleukin-18, 12 and tumor necrosis factor-α in intrahepaticcholestasis of pregnancy. Zhonghua Fu Chan Ke Za Zhi, 2011, vol. 46, no. 5, pp. 329-332.

39. Streetz K., Leifeld L., Grundmann D. et al. Tumor necrosis factor alpha in the pathogenesis of human and murine fulminant hepatic failure. Gastroenterology, 2000, vol. 119, no. 2, pp. 446-460.

40. Grivennikov S.I., Tumanov A.V., Liepinsh D.J. et al. Distinct and nonredundant in vivo functions of TNF produced by t cells and macrophages/neutrophils: protective and deleterious effects. Immunity, 2005, vol. 22, no. 1, pp. 93-104.

41. Iwamoto S., Kido M., Aoki N. et al. TNF-α is essential in the induction of fatal autoimmune hepatitis in mice through upregulation of hepatic CCL20 expression. Clin Immunol, 2013, vol. 146, no. 1, pp. 15-25.

42. Efe C. Drug induced autoimmune hepatitis and TNF-α blocking agents: is there a real relationship? Autoimmun ReVol, 2013, vol. 12, no. 3, pp. 337-339.

43. Ghabril M., Bonkovsky H.L., Kum C. et al. Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol, 2013, vol. 11, no. 5, pp. 558-564.

44. Björnsson E., Talwalkar J., Treeprasertsuk S. et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology, 2010, vol. 51, no. 6, pp. 2040-2048.

45. Weiler-Normann C., Schramm C., Quaas A. et al. Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis. J Hepatol, 2013, vol. 58, no. 3, pp. 529-534.

46. Umekita K., Miyauchi S., Ueno S. et al. Improvement of rheumatoid arthritis and autoimmune hepatitis in a patient treated with the tumor necrosis factor inhibitor, etanercept. Intern Med, 2011, vol. 50, no. 11, pp. 1245-1249.

47. Efe C., Purnak T., Ozaslan E. Anti TNF-alpha therapy can be a novel treatment option in patients with autoimmune hepatitis. Aliment Pharmacol Ther, 2010, vol. 32, no. 1, p. 115.

48. Weiler-Normann C., Wiegard C., Schramm C., Lohse A.W. A case of difficult-to-treat autoimmune hepatitis successfully managed by TNF-alpha blockade. Am J Gastroenterol, 2009, vol. 104, no. 11, pp. 2877-2878.

49. Jones A., Selby P.J., Viner C. Tumour necrosis factor, cholestatic jaundice, and chronic liver disease. Gut, 1990, vol. 31, no. 8, pp. 938-939.

50. Hanada S., Harada M., Koga H. et al. Tumor necrosis factor-alpha and interferon-gamma directly impair epithelial barrier function in cultured mouse cholangiocytes. Liver Int, 2003, vol. 23, no. 1, pp. 3-11.

51. Spadaro A., Scrivo R., Riccieri V., Valesini G. Effect of tumor necrosis factor alpha antagonists in a patient with rheumatoid arthritis and primary biliary cirrhosis. Joint Bone Spine, 2008, vol. 75, no. 1, pp. 87-89.

52. Ogata A., Terabe F., Nakanishi K. Etanercept improved primary biliary cirrhosis associated with rheumatoid arthritis. Joint Bone Spine, 2009, vol. 76, no. 1, pp. 105-107.

53. Kubo S., Iwata S., Saito K., Tanaka Y. Successful treatment of primary biliary cirrhosis with etanercept in a patient with rheumatoid arthritis. Joint Bone Spine, 2011, vol. 78, no. 5, pp. 535-536.

54. Sisman G., Erzin Y., Bal K. Primary biliary cirrhosis developing in a patient with Crohn’s disease during the course of infliximab treatment: The first case in the literature. J Crohns Colitis, 2013, doi: 10.1016/j.crohns.2013.03.003.

55. Ghabril M., Bonkovsky H.L., Kum C. Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol, 2013, vol. 11, no. 5, pp. 558-564.

56. Maggiore G., De Benedetti F., Massa M. et al. Circulating levels of interleukin-6, interleukin-8, and tumor necrosis factor-alpha in children with autoimmune hepatitis. J Pediatr Gastroenterol Nutr, 1995, vol. 20, no. 1, pp. 23-27.

57. Durazzo M., Niro G., Premoli A. et al. Type 1 autoimmune hepatitis and adipokines: new markers for activity and disease progression? J Gastroenterol, 2009, vol. 44, no. 5, pp. 476-482.

58. Wilson A.G., de Vries N., Pociot F. Et al. An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with the HLA A1, B8 and DR3 allelcs. J Exp Med, 1993, vol. 177, no. 2, pp. 557-560.

59. Cookson S., Constantini P.K., Clare M. et al. Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis. Hepatology, 1999, no. 30, pp. 851-856.

60. Czaja A.J., Cookson S., Constantini P.K. et al. Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis. Gastroenterology, 1999, no. 117, pp. 645-652.

61. Bittencourt P.L., Palácios S.A., Cançado E.L. et al. Autoimmune hepatitis in Brazilian patients is not linked to tumor necrosis factor alpha polymorphisms at position -308. J Hepatol, 2001, vol. 35, no 1, pp. 24-28. http://www.ncbi.nlm.nih.gov/pubmed?term=Porta%20G%5BAuthor%5D&cauthor=true&cauthor_uid=11495038

62. Fan L.Y., Zhong R.Q., Tu X.Q. et al. Genetic association of tumor necrosis factor (TNF)-alpha polymorphisms with primary biliary cirrhosis and autoimmune liver diseases in a Chinese population. Zhonghua Gan Zang Bing Za Zhi, 2004, vol. 12, no. 3, pp. 160-162.

63. Béland K., Lapierre P., Alvarez F. Influence of genes, sex, age and environment on the onset of autoimmune hepatitis. World J Gastroenterol, 2009, vol. 15, no. 9, pp. 1025-1034.

64. Tang J., Zhou C., Zhang Z.J., Zheng S.S. Association of polymorphisms in non-classic MHC genes with susceptibility to autoimmune hepatitis. Hepatobiliary Pancreat Dis Int, 2012, vol.11, no. 2, pp. 125-131.

65. Ma X., Qiu D.K. Cytokine gene polymorphisms in Chinese patients with type I autoimmune hepatitis. Zhonghua Gan Zang Bing Za Zhi, 2004, no. 12, pp. 296-298.

66. Yoshizawa K., Ota M., Katsuyama Y. et al. Genetic analysis of the HLA region of Japanese patients with type 1 autoimmune hepatitis. J Hepatol, 2005, no. 42, pp. 578-584.

67. Golovanova E.V., Il’chenko L.Yu., Tsaregorodtseva T.M. and oth. Cytokines in primary biliary cirrhosis (diagnostic and prognostic value). Terapevt. arkh, 2004, no. 2, pp. 8-11. (in Russ.)

68. Kakumu S., Yoshioka K., Tsutsumi Y. et al. Production of tumor necrosis factor, interleukin 1, and interferon-gamma by peripheral blood mononuclear cells from patients with primary biliary cirrhosis. Clin Immunol Immunopathol, 1990, vol. 56, no. 1, pp. 54-65.

69. Wang L., Li Q.M., Du H.H. et al. Correlation study of estrogen receptor with peripheral blood cytokines and serum markers in primary biliary cirrhosis patients. Zhonghua Gan Zang Bing Za Zhi, 2012, vol. 20, no. 5, pp. 336-339.

70. Shirokova E.N. Kholestaz pri khronicheskikh diffuznykh zabolevaniyakh pecheni: patogenez, differentsial’nyi diagnoz, prognosticheskoe znachenie, lechebnaya taktika: avtoref. dis. … d-ra med. nauk [Cholestasis in chronic diffuse liver disease: pathogenesis, differential diagnosis, prognostic value, medical tactic. Synopsis of the dis. Dr. med. sci.]. Moscow, 2009. 41 p.

71. Neuman M., Angulo P., Malkiewicz I. et al. Tumor necrosis factor-alpha and transforming growth factor-beta reflect severity of liver damage in primary biliary cirrhosis. J Gastroenterol Hepatol, 2002, vol. 17, no. 2, pp. 196-202.

72. Hussain M.J., Mustafa A., Gallati H. et al. Cellular expression of tumour necrosis factor-alpha and interferon-gamma in the liver biopsies of children with chronic liver disease. J Hepatol, 1994, vol. 21, no. 5, pp. 816-821.

73. Shondo M., Mullin G. E., Braun-Elwert L. et al. Cytokine mRNA expression in the liver of patients with primary biliary cirrhosis (PBC) and chronic hepatitis B (CHB). Clin Exp Immunol, 1996, no. 105, pp. 254-259.

74. Gordon M.A., Oppenheim E., Camp N.J. et al. Primary biliary cirrhosis shows association with genetic polymorphism of tumour necrosis factor alpha promoter region. Journal of hepatology, 1999, vol. 31, no. 2, pp. 242-247.

75. Jones D.E., Watt F.E., Grove J. et al. Tumour necrosis factor-alpha promoter polymorphisms in primary biliary cirrhosis. J Hepatol, 1999, vol. 30, no. 2, pp. 232-236.

76. Niro G.A., Poli F., Andriulli A. et al. TNF-alpha polymorphisms in primary biliary cirrhosis: a northern and southern Italian experience. Ann N Y Acad Sci, 2009, no. 1173, pp. 557-563.

77. Qin B., Liang Y., Yang Z., Zhong R. Effect of the polymorphisms of tumor necrosis factor-α gene on the susceptibility to primary biliary cirrhosis: a meta-analysis. Eur J Gastroenterol Hepatol, 2012, vol. 24, no. 12, pp. 1386-1392.

78. Chen R., Cai X., Han Z. et al Meta-Analysis: The Relationship between TNF-Alpha Polymorphisms and Susceptibility to Primary Biliary Cirrhosis. Hepatogastroenterology, 2013, vol. 60, no. 123, pp. 568-576.

79. Jeng J.E., Tsai J.F., Chuang L.Y. et al. Tumor necrosis factor alpha 308.2 polymorphism is associated with advanced hepatic fibrosis and higher risk for hepatocellular carcinoma. Neoplasia, 2007, vol. 9, no. 11, pp. 987-992.

80. Tanaka A., Quaranta S., Mattalia A. et al. The tumor necrosis factor-alpha promoter correlates with progression of primary biliary cirrhosis. J Hepatol, 1999, vol. 30, no. 5, pp. 826-829.